| Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ... Nature genetics 47 (5), 505-511, 2015 | 1646 | 2015 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 780 | 2021 |
| DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma A Villanueva, A Portela, S Sayols, C Battiston, Y Hoshida, ... Hepatology 61 (6), 1945-1956, 2015 | 385 | 2015 |
| Cordon-bleu is an actin nucleation factor and controls neuronal morphology R Ahuja, R Pinyol, N Reichenbach, L Custer, J Klingensmith, MM Kessels, ... Cell 131 (2), 337-350, 2007 | 344 | 2007 |
| Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer M Malehmir, D Pfister, S Gallage, M Szydlowska, D Inverso, E Kotsiliti, ... Nature medicine 25 (4), 641-655, 2019 | 317 | 2019 |
| Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma D Sia, B Losic, A Moeini, L Cabellos, K Hao, K Revill, D Bonal, ... Nature communications 6 (1), 6087, 2015 | 299 | 2015 |
| Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial R Pinyol, R Montal, L Bassaganyas, D Sia, T Takayama, GY Chau, ... Gut 68 (6), 1065-1075, 2019 | 226 | 2019 |
| Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma R Montal, D Sia, C Montironi, WQ Leow, R Esteban-Fabró, R Pinyol, ... Journal of hepatology 73 (2), 315-327, 2020 | 197 | 2020 |
| EHD proteins associate with syndapin I and II and such interactions play a crucial role in endosomal recycling A Braun, R Pinyol, R Dahlhaus, D Koch, P Fonarev, BD Grant, ... Molecular biology of the cell 16 (8), 3642-3658, 2005 | 183 | 2005 |
| Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC R Pinyol, D Sia, JM Llovet Clinical Cancer Research 25 (7), 2021-2023, 2019 | 179 | 2019 |
| Molecular pathogenesis and systemic therapies for hepatocellular carcinoma JM Llovet, R Pinyol, RK Kelley, A El-Khoueiry, HL Reeves, XW Wang, ... Nature cancer 3 (4), 386-401, 2022 | 160 | 2022 |
| F-BAR proteins of the syndapin family shape the plasma membrane and are crucial for neuromorphogenesis E Dharmalingam, A Haeckel, R Pinyol, L Schwintzer, D Koch, MM Kessels, ... Journal of Neuroscience 29 (42), 13315-13327, 2009 | 132 | 2009 |
| Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis R Pinyol, S Torrecilla, H Wang, C Montironi, M Piqué-Gili, M Torres-Martin, ... Journal of hepatology 75 (4), 865-878, 2021 | 127 | 2021 |
| Regulation of N-WASP and the Arp2/3 complex by Abp1 controls neuronal morphology R Pinyol, A Haeckel, A Ritter, B Qualmann, MM Kessels PloS one 2 (5), e400, 2007 | 122 | 2007 |
| IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models I Martinez-Quetglas, R Pinyol, D Dauch, S Torrecilla, V Tovar, A Moeini, ... Gastroenterology 151 (6), 1192-1205, 2016 | 120 | 2016 |
| Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification C Montironi, F Castet, PK Haber, R Pinyol, M Torres-Martin, L Torrens, ... Gut 72 (1), 129-140, 2023 | 114 | 2023 |
| Nek9 phosphorylation of NEDD1/GCP-WD contributes to Plk1 control of γ-tubulin recruitment to the mitotic centrosome S Sdelci, M Schütz, R Pinyol, MT Bertran, L Regué, C Caelles, I Vernos, ... Current Biology 22 (16), 1516-1523, 2012 | 99 | 2012 |
| The role of NEDD1 phosphorylation by Aurora A in chromosomal microtubule nucleation and spindle function R Pinyol, J Scrofani, I Vernos Current biology 23 (2), 143-149, 2013 | 80 | 2013 |
| CXCR2 inhibition enables NASH-HCC immunotherapy J Leslie, JBG Mackey, T Jamieson, E Ramon-Gil, TM Drake, F Fercoq, ... Gut 71 (10), 2093-2106, 2022 | 79 | 2022 |
| Liver injury increases the incidence of HCC following AAV gene therapy in mice DA Dalwadi, L Torrens, J Abril-Fornaguera, R Pinyol, C Willoughby, ... Molecular Therapy 29 (2), 680-690, 2021 | 75 | 2021 |
